【摘 要】
：
In cancer,defective differentiation is one of characteristics and targeted for therapy.Compared to general therapeutic strategies with cytotoxic compounds in cancer treatment,the differentiation thera
【机 构】
：
Department of Hematology,Juntendo University School of Medicine
【出 处】
：
The 35th World Congress of the International Society of Hema
论文部分内容阅读
In cancer,defective differentiation is one of characteristics and targeted for therapy.Compared to general therapeutic strategies with cytotoxic compounds in cancer treatment,the differentiation therapy is expected to be less toxicity.The treatment with all-trans retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is currently only clinically applied differentiation therapy.
其他文献
Objective Impaired megakaryocyte maturation and insufficient platelet production participate in the pathogenesis of primary immune thrombocytopenia (ITP).The demethylating agent,decitabine (DAC) has b
Background CLL is one of the most common forms of leukemia among adults.Despite advances in the treatment of CLL,including chemotherapy,chemoimmunotherapy (CIT),and stem cell transplant (SCT),the dise
Background Although chemoimmunotherapy regimens remain the standard in the initial treatment of younger,fit patients with CLL/SLL,relapses are typical.The treatment of older patients,patients with rel
Background Chronic B lymphoproliferative diseases (BLPD),which are mainly compo sed of chronic lymphocytic leukemia (CLL),hairy cell leukemia (HCL),follicular lymphom a (FL),marginal zone lymphoma (MZ
Background A recent GWAS analysis of B-cell chronic lymphocytic leukemia (CLL) identified 12 risk loci,some of which harbor apoptosis-related tumor suppressor genes.Herein we postulate that miR-3151,l
Background The tumor suppressor TP53 is one of the most frequently altered genes in cancer.Several studies have shown TP53 mutations are frequently detected in patients with therapy-related AML or AML
Introduction Donor cell neoplasms are rare complications of treatment regimens that involve stem cell transplantation for hematological malignancies,myelodysplastic processes,or certain genetic or met
Background FLT3 mutation is found in about 30 ％of acute myeloid leukemia (AML) patients and several FLT3 inhibitors are undergoing investigation,but clinical efficacies were lower than expected.In pre
To clarify the prevalence and prognostic significance of c-KIT mutations in patients with core binding factor acute myeloid leukemia (CBF-AML),a total of 351 patients who were categorized into pediatr
Background Recent studies has suggested that high levels of glycolytic metabolism in A ML blasts were associated with resistance to chemotherapy and pateintss survival.TP53-induced glycolysis and apop